Fovea Pharmaceuticals

About Fovea Pharmaceuticals

Fovea Pharmaceuticals SA was a biopharmaceutical company focused on developing and commercializing treatments for ocular diseases, particularly those affecting the retina. The company was founded in May 2005 by a team that included Bernard Gilly, Professor José-Alain Sahel, and Pierre Belichard, with initial seed funding from Sofinnova Partners. Bernard Gilly, who served as Chairman and CEO, brought extensive experience from previous leadership roles at Transgene and as a partner at Sofinnova Partners. Professor Sahel, a renowned researcher in retinal cell degeneration, acted as the Chief Scientific Advisor, providing a strong scientific foundation through a close relationship with the Vision Institute in Paris.

The company's business model centered on identifying and developing drugs for retinal conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. Fovea's strategy involved advancing a diversified pipeline through both internal research and the therapeutic switching of molecules developed for other indications. This approach allowed the company to move rapidly from preclinical to clinical development. By October 2009, Fovea had successfully built a clinical pipeline of three compounds. These included FOV 1101 for persistent allergic conjunctivitis, FOV 2302 for macular edema induced by retinal vein occlusion, and FOV 2304 for diabetic macular edema. The company's operations were financed through two significant funding rounds, a Series A in November 2005 that raised €20.5 million and a Series B in December 2007 for $44 million, attracting a syndicate of European investors.

In a significant milestone, Fovea Pharmaceuticals was acquired by Sanofi-Aventis in October 2009 for a total enterprise value of up to €370 million. The acquisition was structured with an upfront payment and subsequent milestone payments tied to the clinical progress of its compounds. This move provided Sanofi-Aventis with a strategic entry into the ophthalmology market, a sector with growing demand due to an aging population and unmet medical needs. Following the acquisition, Fovea was intended to operate as an independent-style entity within Sanofi, with its management team remaining to lead the new ophthalmology franchise.